These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33324999)

  • 1. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
    Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.
    Nikiforow S; Whangbo JS; Reshef R; Tsai DE; Bunin N; Abu-Arja R; Mahadeo KM; Weng WK; Van Besien K; Loeb D; Nasta SD; Nemecek ER; Zhao W; Sun Y; Galderisi F; Wahlstrom J; Mehta A; Gamelin L; Dinavahi R; Prockop S
    Blood Adv; 2024 Jun; 8(12):3001-3012. PubMed ID: 38625984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
    Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
    Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
    Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
    Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.
    Barlev A; Zimmermann H; Guzman-Becerra N; Mehta A; Xing B; Macabeo B; Thivolet M; Brookhart MA
    J Med Econ; 2024; 27(1):789-795. PubMed ID: 38727527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
    Volaric AK; Saleem A; Younes SF; Zhao S; Natkunam Y
    Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I treat posttransplant lymphoproliferative disorder.
    Amengual JE; Pro B
    Blood; 2023 Oct; 142(17):1426-1437. PubMed ID: 37540819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children.
    Marjańska A; Pogorzała M; Dziedzic M; Czyżewski K; Richert-Przygońska M; Dębski R; Bogiel T; Styczyński J
    Front Immunol; 2024; 15():1427637. PubMed ID: 39055711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
    Zaffiri L; Frankel C; Bush EJ; Neely ML; Pavlisko EN; Mokrova IL; Luftig MA; Palmer SM
    J Med Virol; 2021 Aug; 93(8):5040-5047. PubMed ID: 33704812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders.
    Salmerón-Villalobos J; Castrejón-de-Anta N; Guerra-García P; Ramis-Zaldivar JE; López-Guerra M; Mato S; Colomer D; Diaz-Crespo F; Menarguez J; Garrido-Pontnou M; Andrés M; García-Fernández E; Llavador M; Frigola G; García N; González-Farré B; Martín-Guerrero I; Garrido-Colino C; Astigarraga I; Fernández A; Verdú-Amorós J; González-Muñíz S; González B; Celis V; Campo E; Balagué O; Salaverria I
    Blood; 2023 Aug; 142(5):434-445. PubMed ID: 37053555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-Cell Posttransplant Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Systemic Review.
    Jiang C; Huang J; Shao J; Yang T; Zhao Y; Huang M; Yi H; Shi J; Wan L; Chen F; Cao Y; Hu X
    Cell Transplant; 2024; 33():9636897241259722. PubMed ID: 38856035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.
    O'Reilly RJ; Prockop S; Oved JH
    Front Immunol; 2023; 14():1290059. PubMed ID: 38274824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres.
    Santarsieri A; Rudge JF; Amin I; Gelson W; Parmar J; Pettit S; Sharkey L; Uttenthal BJ; Follows GA
    Br J Haematol; 2022 May; 197(3):310-319. PubMed ID: 35235680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating Between Epstein-Barr Virus-positive Lymphoid Neoplasm Relapse and Post-transplant Lymphoproliferative Disorder After Sex-mismatched Hematopoietic Stem Cell Transplantation.
    Kurashige R; Kurashige M; Okada Y; Higuchi K; Yuda S; Hino A; Miyamura T; Ichii M; Fukushima K; Honma K; Takeuchi M; Yokota T; Ishikawa J; Sawada A; Shibayama H; Hosen N; Morii E
    Am J Surg Pathol; 2024 Apr; 48(4):395-405. PubMed ID: 38287877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoproliferative Disorders after Lung Transplantation: Clinicopathological Characterization of 16 Cases with Identification of Very-Late-Onset Forms.
    Thomas de Montpréville V; Le Pavec J; Le Roy Ladurie F; Crutu A; Mussot S; Fabre D; Mercier O; Dorfmuller P; Ghigna MR; Fadel É
    Respiration; 2015; 90(6):451-459. PubMed ID: 26506523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.
    Weinberg OK; Pinkus GC; Ramos-Gonzalez GJ; Agur T; Rodig NM
    Clin Transplant; 2023 Dec; 37(12):e15134. PubMed ID: 37772613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
    Marcelis L; Antoranz A; Delsupehe AM; Biesemans P; Ferreiro JF; Debackere K; Vandenberghe P; Verhoef G; Gheysens O; Cattoretti G; Bosisio FM; Sagaert X; Dierickx D; Tousseyn T
    Cancer Immunol Immunother; 2020 Sep; 69(9):1751-1766. PubMed ID: 32335702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Transplant Lymphoproliferative Disorders.
    Dharnidharka VR; Ruzinova MB; Marks LJ
    Semin Nephrol; 2024 Jan; 44(1):151503. PubMed ID: 38519279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
    Bollard CM; Rooney CM; Heslop HE
    Nat Rev Clin Oncol; 2012 Sep; 9(9):510-9. PubMed ID: 22801669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV-associated lymphoproliferative disease post-CAR-T cell therapy.
    Zhang S; Zhou X; Zhang S; Wang N; Zhang T; Zhang D; Ao Q; Cao Y; Huang L
    Front Med; 2024 Apr; 18(2):394-398. PubMed ID: 38329597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.